Zanubrutinib - BeiGene

Drug Profile

Zanubrutinib - BeiGene

Alternative Names: BGB-3111

Latest Information Update: 15 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BeiGene
  • Developer BeiGene; Peter MacCallum Cancer Centre
  • Class Amides; Antineoplastics; Piperidines; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Waldenstrom's macroglobulinaemia; Mantle-cell lymphoma; Chronic lymphocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Chronic lymphocytic leukaemia; Mantle-cell lymphoma
  • Phase III Waldenstrom's macroglobulinaemia
  • Phase II Diffuse large B cell lymphoma; Follicular lymphoma
  • Phase I/II Lymphoma
  • Phase I B cell lymphoma

Most Recent Events

  • 07 Nov 2018 BeiGene plans a phase II trial for Lymphoma
  • 05 Nov 2018 Phase-III clinical trials in Chronic lymphocytic leukaemia (Second-line therapy or greater) in USA (PO)(NCT03734016)
  • 24 Oct 2018 Preregistration for Chronic lymphocytic leukaemia (Second-line therapy or greater) in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top